Wafik S. El-Deiry: Informative discussions at WIN Consortium in cancer personalized medicine International Molecular Tumor Board
Wafik S. El-Deiry shared a post on LinkedIn:
“Incredibly informative discussions at today’s well-attended WIN Consortium in cancer personalized medicine International Molecular Tumor Board.
Discussions provided helpful input regarding individualized management and treatment of complicated oncology cases with molecular data.
Today we discussed a case of metastatic colorectal cancer with WT KRAS/BRAF/NRAS in a present setting of de-escalation as well as plans for future therapy after evidence suggesting progression prompted further work up relevant to management.
The second case was an incredibly unique case and diagnostic dilemma where input at today’s meeting from Drs. Razelle Kurzrock, Thomas Ollila, Deana Treaba, and Liang Cheng was incredibly helpful.
Wafik El-Deiry, MD, PhD, FACP, FRSM, is the Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Director of the Legorreta Cancer Center at Brown University and Director of the Joint Program in Cancer Biology at Brown University and affiliated hospitals.
Dr. El-Deiry discovered p21(WAF1) as a p53 target gene, cell cycle inhibitor, and tumor suppressor that explained the mammalian cell stress response. Dr. El-Deiry’s research is focused on mechanisms of therapy resistance with major efforts in drug discovery and development.